Pfizer Head of R&D Business Development – Asia Alex Fowkes On Matching Global Partners With Pfizer’s Pipeline: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Pfizer's Head of R&D Business Development - Asia Alex Fowkes sat down with PharmAsia News' Australia bureau to discuss Pfizer's business development and research strategies in Asia. Fowkes recently addressed a panel at the BioAsia conference in Singapore and discussed Pfizer's virtual approach to doing business in Asia, which offers more flexibility and creative approaches (PharmAsia News, May 8, 2008).
You may also be interested in...
Pfizer Senior VP And Head Of Worldwide PharmaTherapeutics Research Rod MacKenzie On Moving R&D To China: An Interview With PharmAsia News (Part 1 of 2)
Pfizer Inc.'s Rod MacKenzie, senior VP and Head of Worldwide PharmaTherapeutics Research talked with PharmAsia News about the evolution of Pfizer's virtual R&D approach in China and larger Asia. Pfizer announced last week that it would be opening a new R&D center for antibacterials in Shanghai after closing its antibacterial R&D plant in Groton, Conn. The move marks the first dedicated R&D unit for a specific therapy area in Asia.
Pfizer Senior VP And Head Of Worldwide PharmaTherapeutics Research Rod MacKenzie On Moving R&D To China: An Interview With PharmAsia News (Part 1 of 2)
Pfizer Inc.'s Rod MacKenzie, senior VP and Head of Worldwide PharmaTherapeutics Research talked with PharmAsia News about the evolution of Pfizer's virtual R&D approach in China and larger Asia. Pfizer announced last week that it would be opening a new R&D center for antibacterials in Shanghai after closing its antibacterial R&D plant in Groton, Conn. The move marks the first dedicated R&D unit for a specific therapy area in Asia.
Discovery Research In Japan By Global Pharmas: Evolving More Toward Partnerships? (Part 1 of 3)
While some globe-spanning pharmaceutical companies are maintaining or increasing their investment in discovery research in Japan, many more are moving in the opposite direction.